R&D News | pharmaphorum

News

Woman with breast cancer covering her chest with her hands

Enhertu poised to move first line in HER2+ breast cancer

New data could make HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the first time.

News

Vials on a conveyor belt - pharma manufacturing

Trodelvy-Keytruda pairing hits the spot in breast cancer

Gilead Sciences has cemented the role of its TROP2 drug Trodelvy in triple-negative breast cancer with a study win in combination with MSD's Keytruda.

News

Merida raises $121m for Graves drug, and other financings

Our round-up of recent biotech financings includes rounds for Merida, Glycomine, Attovia, Imbria, and Solu Therapeutics.

News

Lilly soars on first data for oral obesity candidate

Shares in Eli Lilly rose sharply in pre-market trading today after it reported phase 3 results for oral diabetes and weight-loss drug orforglipron.

News

Spruce Bio sows the seeds of its new future

Spruce has bounced back from the failure of its lead drug last year, thanks to a licensing deal with BioMarin for a late-stage Sanfilippo drug.

News

Rush hour of commuters at London station

UK Biobank responds to fears over Chinese access to NHS data

Access to de-identified NHS patient data by researchers based in China is not a security concern, according to UK Biobank.

Enhertu poised to move first line in HER2+ breast cancer

Trodelvy-Keytruda pairing hits the spot in breast cancer

Merida raises $121m for Graves drug, and other financings

Lilly soars on first data for oral obesity candidate

Spruce Bio sows the seeds of its new future

UK Biobank responds to fears over Chinese access to NHS data

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks